LAVA Therapeutics
Founded 2016 · 7 employees on LinkedIn · 7 known investors
LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
Founders & leadership
LAVA Therapeutics was founded in 2016 by Ton Adang and Hans van der Vliet.
Investors · 7
MRL Ventures FundCambridge · $25M
Sanofi VenturesCambridge · $5M
Ysios CapitalBarcelona · $5.4M – $21.6M
Gilde HealthcarereportedUtrecht · $1.1M – $55M
REDMILEreportedSan Francisco
Also in the syndicate · 2
BB Pureos BioventuresVersant
Funding
SEC filings, press & company announcements- Undisclosed amountSeries CSep 2020
Novo Ventures (lead), Sanofi Ventures (lead), BB Pureos Bioventures, Gilde Healthcare, MRL Ventures Fund, LLC, Redmile Group, LLC, Versant, Ysios Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does LAVA Therapeutics do?
- LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
- Who founded LAVA Therapeutics?
- LAVA Therapeutics was founded by Ton Adang, Hans van der Vliet in 2016.
- Who are LAVA Therapeutics's investors?
- LAVA Therapeutics's investors include MRL Ventures Fund, Sanofi Ventures, Ysios Capital, Gilde Healthcare, REDMILE.






